申请人:Neurogen Corporation
公开号:US05696260A1
公开(公告)日:1997-12-09
Disclosed are compounds of the formula: ##STR1## or pharmaceutically acceptable non-toxic salts thereof wherein: R.sub.9 and Y are substituents as defined herein; and R.sub.a and R.sub.b independently represent halogen, hydroxy, amino, mono or dialkylamino where each alkyl is straight or branched chain alkyl having 1-6 carbon atoms, straight or branched chain lower alkyl having 1-6 chain atoms, or straight or branched chain lower alkoxy having 1-6 carbon atoms, where R.sub.a and R.sub.b each appear at most only once on the phenyl ring which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine type drugs, and enhancement of alertness.
本发明涉及以下化合物:##STR1##或其药学上可接受的非毒性盐,其中:R.sub.9和Y是如本文所定义的取代基;R.sub.a和R.sub.b独立地表示卤素,羟基,氨基,单烷基或二烷基氨基,其中每个烷基是直链或支链烷基,具有1-6个碳原子,直链或支链较低烷基,具有1-6个链原子,或直链或支链较低烷氧基,具有1-6个碳原子,在苯环上R.sub.a和R.sub.b最多只出现一次。这些化合物是高度选择性的GABAa脑受体的激动剂,拮抗剂或反向激动剂,或其前药,可用于诊断和治疗焦虑,睡眠和癫痫障碍,苯二氮䓬类药物的过量和增强警觉性。